Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05854563 · ClinicalTrials.gov registry record

Cough Capture as a Portal Into the Lung

A clinical trial of Lung Cancer and Lung Diseases, sponsored by Albert Einstein College of Medicine.

Recruiting
Registry status
2,000
Enrollment target
1
Study location

NCT05854563: Recruiting study of Lung Cancer and Lung Diseases, sponsored by Albert Einstein College of Medicine.

NCT05854563 is a study of Lung Cancer and Lung Diseases that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 2,000 participants, above the 931-participant average among 409 other Lung Cancer trials with a reported enrollment target (115% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05854563, a study of Lung Cancer and Lung Diseases, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.

RECRUITING
Registry status
2,000 participants
Enrollment target
1
Study location

Study Summary

The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection/risk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP/SFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications. The investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg/Maslov labs. Finally, the investigator team will (Aim 3) test all

Primary Outcome

Somatic DNA analysis will be conducted using Single Molecule Mutation sequencing (SMM-seq) to identify mutations in EV-partitioned cough samples. The number will be determined by statistical testing using Fishers Exact Test to determine if there is a nonrandom association between the two variables

Interventions

  • OTHER Observational only, all subjects; measure DNA mutation and proteomic survey.

Study Locations (1)

New York

  • Albert Einstein College of Medicine - The Bronx

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2023-03-28
Est. Completion 2027-06
Albert Einstein College of Medicine

175 total trials

What NCT05854563 shows while recruiting

NCT05854563 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 931-participant average among 409 other Lung Cancer trials with a reported enrollment target (115% higher).

The record links to 5 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observational only, all subjects; measure DNA mutation and proteomic survey. is the first listed.

NCT05854563 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05854563 about?

NCT05854563 is a clinical study titled "Cough Capture as a Portal Into the Lung". The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection/risk assessment and diagnostic purposes. However, large macromol...

What is the current status of trial NCT05854563?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2023-03-28. Estimated completion is 2027-06.

What conditions does trial NCT05854563 study?

This clinical trial studies the following conditions: Lung Cancer, Lung Diseases, Lung Diseases, Interstitial, Lung Diseases, Obstructive, Lung Inflammation.

What interventions are being tested in trial NCT05854563?

The interventions under investigation include: Observational only, all subjects; measure DNA mutation and proteomic survey. (OTHER).

Who is sponsoring clinical trial NCT05854563?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05854563 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05854563's enrollment target sits among peer trials

2,000 28th of 409 higher than 380 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05854563, the US trial registry maintained by the National Library of Medicine. NCT05854563 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.